According to the United States Preventive Services Task Force, PSA -- which actually stands for "prostate specific antigen" -- might as well mean "please stop asking!" Please stop asking whether or not men have prostate cancer by using this test, in other words, because it is tantamount to asking for trouble.
The news that the highly regarded Task Force now officially recommends against screening for prostate cancer has already proved upsetting to some, and will doubtless prove so to many others as they learn of the new report.
And we can certainly understand why. There are people I know, perhaps people you know, and some celebrities we all know who may have had their lives -- or the life of a loved one -- saved by PSA screening. Certainly those who wound up being treated for prostate cancer because of an elevated PSA are convinced they owe their life to the test.
Can they, and the Task Force, both be right? Paradoxical as it may seem, i believe the answer is: yes.
For starters, the prostate specific antigen is a protein specific to the prostate, but not to prostate cancer. Levels of PSA in the blood vary in normal, healthy men; and can rise with benign enlargement of the prostate. These values overlap the values seen with prostate cancer.
A truly specific test is one that only generates an abnormal result when the disease in question is present. Such a test is very useful at ruling disease in, because it will almost never be positive when disease is absent- and thus if positive, the test reliably rules in disease. Alas, the PSA is not such a test. The result of the test's relatively low specificity is that many men without prostate cancer wind up having unnecessary biopsies, and sometimes, complications of those biopsies.
The PSA might still be useful if it were highly sensitive. A highly sensitive test is reliably abnormal when disease is present. When a highly sensitive test result is normal, it is a very reliable indicator that disease is truly absent. But again, the PSA falls short. Levels in many cases of prostate cancer are not appreciably different from levels seen in normal men -- and thus the test cannot be counted on to rule disease out either.
But I believe the most important failing of the PSA is not so much about its use in detecting disease, but rather the problem of knowing what to do about prostate cancer when it is found.
Cancer screening, or for that matter any disease screening, is, in the most literal sense, looking for trouble. Looking for trouble makes sense if by finding it early you can fix it. But if you don't know what to do with the trouble you find, you are no longer just looking for trouble -- you are asking for trouble, too.
Prostate cancer is unpredictable. More often than not, it does not grow or progress. In fact, as many as 80 percent of men who live past age 80 have prostate cancer when they die and most never know it. But, of course, some prostate cancers DO grow, spread and kill. Thousands of men die prematurely of prostate cancer each year in the U.S.
The real trouble with looking for this particular trouble is that we can't reliably tell these varieties apart. The result is that PSA screening results in treatment for prostate cancer that doesn't need treatment, as well as those cases that do. And the result of that is avoidable harms, including impotence, dysfunction of bladder and bowel, post-operative infections, and so on. Some of those people we know who are convinced PSA testing saved their lives may be right. But others are wrong; their prostate cancer would never have troubled them if left undetected, whereas they are left to live out their lives with the complications of unneeded surgery. Some of the staunchest defenders of PSA screening are, in fact, casualties of it -- but don't realize it.
I am a preventive medicine specialist. I also happen to be a man well past 40 who owns a prostate -- and to make this personal, I have NOT opted for prostate cancer screening, because I am familiar with the evidence on which the USPSTF is basing its current recommendation.
I am, of course, also familiar with the high-profile stories of PSA testing seemingly saving lives -- and I know that on occasion, it truly does so. How to reconcile those two?
Probabilistically, and proactively.
In terms of probability, PSA screening may, in fact, save lives. But the question is: is it more likely to save my life, or cause me harm?
There are specific calculations to help sort out just such dilemmas. The most useful and intuitive are the number needed to treat (NNT), and number needed to harm (NNH). The former measure indicates how many people need to undergo a treatment or test, and face its potential risks, before one person actually benefits. The latter says how many people are harmed for every one who is helped.
There are various published estimates of the NNT and NNH for prostate cancer screening. The Task Force conclusion is simply that the NNT is too high, and the NNH too low to justify routine use of the test.
Which brings us to the most uncomfortable part of all this. Isn't the Task Force trading off the lives of individuals who could be saved against a less important "population level" effect?
It may feel that way, but it's not so. Let's illuminate why through the time-honored technique of reductio ad absurdum.
Occasionally, someone with no prior signs of heart disease experiences sudden cardiac death that coronary bypass surgery might have prevented. We might, therefore, simply open up the chests of everyone at age 25, or 30, or 35, on the chance that they were the rare individual facing such a fate. The gummed up coronaries could be bypassed, probably saving a life -- while everyone else's chest would simply be closed up again. Alternatively, we know some people develop advanced cancer without showing signs of it in early stages. We might simply give everyone prophylactic chemotherapy to make sure such cases don't sneak by. This would be harmful to everyone without cancer, but might save the life of someone with a nascent cancer as yet undetected.
I am confident no one would sanction such approaches. Even knowing I might be the rare individual prone to sudden cardiac death, I would not want to undergo open heart surgery "just in case," and I would certainly not want to be the one to wake up and find an "oops, not necessary!" note on my sewn up chest. We can acknowledge that an occasional life might be saved by such practices -- but the human cost would simply be too high.
In fact, even something as trivial as discomfort -- or dollars -- can make the cost too high. We all hear occasional stories of a stray bullet killing an innocent bystander. This might be prevented if every one of us were to wear a bullet proof vest every day. This would be uncomfortable, and costly. But the real reason we don't do it is =- the probability of any one of us being that victim is simply too low to justify the inconvenience.
PSA screening as a matter of routine is, of course, far less extreme than coronary bypass or chemotherapy -- but the difference is one of degree, not kind. For a screening test to be useful, it must be applied widely, so the relatively uncommon person who actually has the disease is found. We don't know in advance who that person is =- so we have to go looking for him in a crowd. But the result of such widespread application is that many people will be exposed to the test -- and whatever harms are attached to it.
For better or worse, then, how we care well for any one body is inextricably tied up with implications for the body politic. It simply doesn't make sense to impose on a population an approach that does more harm than good.
This is not a statement of social or political preference, and has nothing to do with ideology. It is a matter of statistical probability. When the result of testing is net harm, any one person tested is more apt to be harmed than helped. PSA testing in all men -- like bullet proof vests for us all, every day -- truly can save an occasional life. But that doesn't mean the approach is warranted. The Task Force relies on data, and boldly confronts the implications. Their conclusions may inspire passion in others, but the conclusions themselves are dispassionate and objective. Tempting as it may be to oppose an evidence-based conclusion with passion, conviction and wishful thinking -- we do so at our collective, and individual peril.
There is, though, a constructive, and pro-active response to bad news about prostate cancer screening. Screening, at best, finds cancer early -- it does not prevent it outright. There appears to be good opportunity for the outright prevention of prostate cancer -- and/or the prevention of its progression if it does development -- by the "usual" means: eating well, being active and controlling weight.
More provocative is evidence from studies in early stage prostate cancer that lifestyle factors can alter gene expression -- down-regulating cancer promoter genes, up-regulating cancer suppressor genes. Such findings indicate that the course of prostate cancer can be modified at the very level of our genes by the power of food and exercise as medicine. We are not defenseless.
I believe the United States Preventive Services Task Force has no axe to grind. They are not motivated by politics, or economics. When looking for the trouble of cancer is advisable, they recommend it. When looking for such trouble is asking for trouble, they say so -- and don't mince words. It's my opinion that we would be well advised to listen.
-fin
Dr. David L. Katz; www.davidkatzmd.com
www.turnthetidefoundation.org
Follow David Katz, M.D. on Twitter: www.twitter.com/DrDavidKatz
David Katz, M.D.: Omission, Commission & Medical Outcomes: PSA And Sin Selection
http://www.huffingtonpost.com/david-katz-md/psa-screening_b_1002232.html
Doctors, please think before you speak if not of yourselves, then of the ones who love you, if you are lucky enough to have such people in your life.
I'm opting for the surgery.
What the Task Force is telling us- and the inventor of the PSA assay agrees with them entirely- is that the test never worked as well as we hoped; that it has resulted in some good, but more harm- and it probably never should have been approved in the first place.
Finally, use of the test to monitor status AFTER a biopsy or treatment is altogether different from using it to screen for disease, and is not a part of this debate.
We recall cribs in this country because a handful of children die as a result of a design flaw but you are advising men not to take a PSA that may save thousands of lives a year? Who cares about the monetary cost? Even if a PSA saved one life a year the cost would be well worth it! Please stop telling men not to take routine PSA's and for goodness sake have one yourself. The cost is minimal compared to losing a family member! By the way...why not do away with mammograms also. they are expensive, inconclusive and can lead to unnecessary and invasive biopsies, radiation, chemotherapy and other treatments that may ultimately have no benefit?
I encourage all newly diagnosed men to obtain unbiased information from this website:
http://www.ustoo.org/newly_diagnosed.asp
Many tests in medicine are controversial. For example, should we screen for lung cancer with routine chest x-rays? Clearly we would identify some asymptomatic cases and initiate lifesaving treatments. But it's been clearly demonstrated that many more benign lesions than cancerous lesions would be found. Most of these lesions would require multiple CT scans which over time would contribute to development of malignancies in some. Many more benign than cancerous lesions would ultimately be surgically resected. A few folks would have severe complications and possibly die from resection of these benign radiographic findings. Ultimately the medial community concluded that the risks outweigh the potential benefits of screening for lung cancer with chest x-ray. Nowadays there is huge debate on whether targeted screening of high-risk patients (i.e,. smokers) with chest CT scans is beneficial. One recent study suggests that on a population level the answer may be yes. However, one study is generally considered inadequate evidence to make sweeping policy changes.
Universal screening of YOUNGER women does not satisfy these criteria. The more dense fibrous breast tissue of young women means detecting cancers is difficult. Furthermore, breast cancer is rare in young women who don't have strong family histories. Screening mammograms in this population results in a high ratio of false positive to true positive tests which result in biopsies. There is some evidence that prior breast biopsy is a risk factor for subsequent breast cancer. In the younger population a better approach is to target individuals at risk for familial breast cancer.
http://sunshine625.hubpages.com/hub/Prostate-Cancer-Doctors-Are-Still-Clueless
It's interesting to compare the public's reaction to this decision with recommendations for vaccinations. The general public generally has a strong suspicion against vaccinations and takes tremendous convincing before a significant portion of the population agrees to vaccination. However, this test seems so benign since it's just a blood test that it's true significance is missed by the general public and even many providers. I suspect that if a group tried to convince everyone to receive a vaccine with evidence of benefit this poor the population would be outraged.
Finally, the task force has put ZERO pressure on me. I am a fellowship trained internist with expertise in interpreting medical literature. I can read studies and make my own conclusions. And I agree with USPSTF on this one.
Treating prostate cancer, especially in older men, is often similar. "Treatment" offers nothing but harm for many (but not all) individuals who live with this malady.
In order for a test to be a good screen a sufficiently long interval must exist between when a condition is detectable and treatable and when the condition will progress. Most prostate cancers progress slowly and predictably and may be detected by PSA screening. Most of these are not aggressive and many could be safely treated via "watchful waiting". Unfortunately some younger men develop an aggressive form of the disease which spreads early. It is possible to have a normal DRE and PSA one year and metastatic cancer by the next year's exam. In these situations the screening tests are not effective for prolonging life. The test may suggest a cancer's presence but not in a sufficient time to cure it. Aggressive cancers in relatively young men often behave fundamentally different than the bulk of these disease seen in older patients.
At the population level there will be individuals who benefit from PSA screening. Understandably many of those diagnosed with localized cancer who pursued cures believe that the test saved their life. But their conviction does not prove them right. Knowing which cancer will remain localized and will behave aggressively but hasn't yet done so cannot be determined with the current PSA assay unfortunately.